← Option Care Health overview

Option Care Health vs Adapthealth: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Option Care Health Inc (OPCH)

Q3 2026
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

August 2026
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

Latest
▲3▼1

Option Care agrees to $5.8B buyout by McKesson and CD&R

  • Confirmed $32.05/share buyout ends standalone uncertainty Option Care agreed to be acquired by McKesson and CD&R for $32.05 a share in cash, about a 37% premium, valuing it near $5.8 billion. The stock jumped 32.7% to close at $31, near the offer price, because the deal caps the painful standalone slump and gives shareholders a certain payout.

    This is the single biggest new event and the main reason OPCH is moving now.

  • Takeover talks first surfaced, stock spiked 22% On October 5, the Financial Times reported McKesson and private equity firm CD&R were in advanced talks to buy Option Care for over $5 billion, with CD&R taking 51% and McKesson 49%. Shares jumped 22% after hours, starting the move that ended in the confirmed deal.

    It is the first report of the deal that drove the period's sharp move, distinct from the final agreement.

  • Q2 earnings rose and full-year outlook reaffirmed Option Care reported second-quarter net income up 6.7% to $53.9 million and adjusted earnings per share up 9.8% to $0.45, while reaffirming full-year 2026 revenue of $5.675–$5.775 billion. Shares rose over 6% as results beat worries and guidance held steady.

    It shows the underlying business was still growing before the buyout, a real support for the stock.

  • Fund exit flagged reimbursement and volume pressures Madison Small Cap Fund sold its Option Care stake, citing reimbursement delays, falling therapy volume, biosimilar pricing pressure and the loss of a profitable specialty drug. The stock had fallen 25% over 52 weeks, showing why a buyout at a premium was welcomed by long-suffering holders.

    It is the main counterweight explaining the weak standalone backdrop behind the buyout.

Adapthealth Corp (AHCO)

Q3 2026
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.

August 2026
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.

Latest
▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

  • Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.

    This is the single biggest new force behind AHCO's price drop this period.

  • Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.

    Cash flow weakness and legal risk are new, concrete reasons investors are selling.

  • Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.

    This is a major new strategic move that could support the stock by simplifying the company.

  • New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.

    A new CFO is a new event that could affect how investors view the company's financial credibility.